Stockscreener 앱 받기
71.00
7.01%
4.65
시간 외 거래:
69.97
-1.03
-1.45%
전일 마감가:
$66.35
열려 있는:
$63.33
하루 거래량:
4.74M
Relative Volume:
4.77
시가총액:
$1.44B
수익:
$90.12M
순이익/손실:
$-276.06M
주가수익비율:
-48.63
EPS:
-1.46
순현금흐름:
$-193.47M
1주 성능:
+102.16%
1개월 성능:
+83.13%
6개월 성능:
+200.85%
1년 성능:
+9,613%
1일 변동 폭
$62.00
$72.31
1주일 범위
$34.47
$72.31
52주 변동 폭
$0.432
$72.31
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
71.00 | 1.35B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-26 | 개시 | Citigroup | Buy |
| 2025-06-24 | 재확인 | BTIG Research | Buy |
| 2025-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-03-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-01-08 | 개시 | B. Riley Securities | Buy |
| 2024-12-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-04 | 개시 | Piper Sandler | Overweight |
| 2024-09-30 | 재개 | BTIG Research | Buy |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-11-09 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 재개 | Jefferies | Hold |
| 2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 개시 | BofA Securities | Neutral |
| 2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-09-14 | 개시 | JP Morgan | Neutral |
| 2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
| 2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
| 2020-04-22 | 개시 | The Benchmark Company | Buy |
| 2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
| 2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 재확인 | H.C. Wainwright | Buy |
| 2018-04-20 | 개시 | Seaport Global Securities | Buy |
| 2018-04-13 | 재개 | Piper Jaffray | Overweight |
| 2018-04-06 | 재확인 | Mizuho | Buy |
| 2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
Nektar CEO looks to add $400 milllion for atopic dermatitis drug - The Business Journals
Nektar Therapeutics stock falls after $400 million public offering By Investing.com - Investing.com UK
Nektar Therapeutics (NKTR) Is Up 88.9% After Upsized Equity Raise And Positive REZOLVE-AD DataHas The Bull Case Changed? - simplywall.st
Nektar Therapeutics (NASDAQ:NKTR) Sets New 12-Month HighHere's Why - MarketBeat
Nektar Therapeutics' (NASDAQ:NKTR) Shares Climb 81% But Its Business Is Yet to Catch Up - simplywall.st
HC Wainwright Expects Lower Earnings for Nektar Therapeutics - MarketBeat
Nektar Therapeutics Prices $400 Million Offering of Stock, Pre-Funded Warrants - marketscreener.com
Nektar Therapeutics prices $400M stock offering - MSN
Nektar Therapeutics (NKTR) Finalizes $400M Stock Offering - GuruFocus
Nektar Therapeutics announces pricing of upsized $400 million public offering - marketscreener.com
Nektar Therapeutics Announces Pricing Of Upsized $400 Million Public Offering - TradingView
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering - PR Newswire
Nektar Therapeutics stock hits 52-week high at 66.97 USD By Investing.com - Investing.com Nigeria
Nektar Therapeutics Announces Proposed Public Offering - The Malaysian Reserve
Rezpegaldesleukin maintenance data show durable responses in moderate-to-severe atopic dermatitis - Contemporary Pediatrics
Nektar Therapeutics stock pops on $300M equity offering - MSN
Nektar Stock Soars Amid Promising Developments and Analyst Upgrades - StocksToTrade
Nektar seeks US$300m for promising eczema drug - ifr-logo
Nektar Therapeutics stock hits 52-week high at 66.97 USD - Investing.com
Nektar Stock Surges On Rezpegaldesleukin Phase 2b Maintenance Data: What It Means - Seeking Alpha
Nektar’s Rezpegaldesleukin Shows Promise, Analysts Raise Price Targets - timothysykes.com
Nektar Therapeutics (NASDAQ:NKTR) Sees Unusually-High Trading Volume on Analyst Upgrade - MarketBeat
BTIG Lifts Nektar Price Target Amidst Promising Atopic Dermatitis Treatment - StocksToTrade
Nektar Therapeutics (NKTR) Shares Surge on $300M Public Offering Announcement - GuruFocus
Nektar’s Rezpeg Differentiates in Atopic Dermatitis With Durable, Deep Responses in Mid-Stage - BioSpace
A Quick Look at Today's Ratings for Nektar Therapeutics(NKTR.US), With a Forecast Between $102 to $165 - 富途牛牛
Nektar Shares Surge On Phase IIb Rezpeg Atopic Dermatitis Data - Citeline News & Insights
Nektar’s stock rises 51% on Phase II Rezpeg AD maintenance win - Yahoo Finance
Q3 EPS Forecast for Nektar Therapeutics Boosted by Analyst - MarketBeat
Why Is Nektar Therapeutics Stock Gaining Wednesday? - Benzinga
Biopharma companies Evommune and Nektar soar on eczema treatment data - Mugglehead Investment Magazine
Nektar Therapeutics (NKTR) stock jumps again premarket after 51% surge; $300 million offering in focus - Bez Kabli
Nektar reports positive long-term data for atopic dermatitis drug By Investing.com - Investing.com South Africa
Nektar Therapeutics announces $300 million public offering By Investing.com - Investing.com South Africa
Nektar Therapeutics Touts 52-Week ResPEG Data in Atopic Dermatitis, Eyes Phase 3 Launch in Q2 - MarketBeat
BTIG Maintains Buy on Nektar Therapeutics (NKTR) Feb 2026 - Meyka
Nektar Therapeutics (NKTR) Launches $300M Stock Offering - GuruFocus
Nektar Therapeutics stock price target raised to $151 by BTIG - Investing.com UK
Evommune, Nektar assets join list of recent successes in atopic derm - BioCentury
Evommune, Nektar soar on atopic dermatitis phase II data - BioWorld MedTech
Nektar Therapeutics announces $300 million public offering - Investing.com
Maintenance results boost Nektar's case for IL-2 agonist in atopic dermatitis - FirstWord Pharma
Nektar Therapeutics launches $300 mln equity offering after stock soars - TradingView
Double Trouble For Dupixent? Biotechs Fly On Eczema Tests. - Investor's Business Daily
Nektar Therapeutics (NKTR) Receives Boost with Analyst PT Raise | NKTR Stock News - GuruFocus
Nektar Therapeutics (NKTR) Analyst Rating Update: Price Target R - GuruFocus
BTIG Research Increases Nektar Therapeutics (NASDAQ:NKTR) Price Target to $151.00 - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Given New $165.00 Price Target at HC Wainwright - MarketBeat
Nektar Therapeutics stock price target raised to $151 by BTIG By Investing.com - Investing.com India
William Blair upgrades Nektar Therapeutics stock rating to Outperform By Investing.com - Investing.com Canada
Biotech Stock Nektar Therapeutics (Nasdaq: NKTR) Makes Top Gainer List on News of REZOLVE-AD study - Investorideas.com
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):